Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon Regulation of Lipoprotein Production
NCT01155206Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2009
- Primary completion
- Jan 2010
- Countries
- 1
- Sponsor
- University Health Network
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Drugs
- glucagon
- Conditions
- type 2 diabetes mellitus (T2DM)hypertriglyceridemia
01
Overview
Phase 4, randomised trial of glucagon in type 2 diabetes mellitus (T2DM) and hypertriglyceridemia, sponsored by University Health Network. Primary endpoint: Triglyceride-rich lipoprotein production rate. Started Jun 2009; status: completed.
02
Design
- Study design
- Randomized
03
Who it enrols
Healthy lean adults (BMI 20-25) aged 18-40 with normal glucose tolerance and no significant systemic disease or medication use.
04
Endpoints
Primary
Triglyceride-rich lipoprotein production rate
Beyond the preview
Go deeper on NCT01155206.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01155206.